OTC Markets OTCPK - Delayed Quote USD

Data Call Technologies, Inc. (DCLT)

0.0022

0.0000

(0.00%)

At close: December 20 at 3:00:00 PM EST

The comeback of REITs: Top ways to play commercial real estate

Recent indications from the Federal Reserve of fewer rate cuts next year have served as a reality check for commercial real estate. But the sector may finally regain momentum in 2025.

Yahoo Finance 10 hours ago

EXR

AHR

PLD
Donald Trump’s Agenda Has New Enforcers: Charlie Kirk and a Legion of Influencers

On podcasts, posts and college campuses, conservatives push their worldview and the president-elect’s policies.

The Wall Street Journal 1 hour ago

RUM

RUMBW
Is Occidental Petroleum (OXY) the Top Oil and Gas Stock To Invest In According to Hedge Funds?

We recently published a list of Top 12 Oil and Gas Stocks To Invest In According to Hedge Funds. In this article, we are going to take a look at where Occidental Petroleum Corporation (NYSE:OXY) stands against oil and gas stocks to invest in according to hedge funds. With a record average production of 12.9 […]

Insider Monkey 8 hours ago

OXY
Prediction: These 2 Stocks Will Join the S&P 500 in 2025

The Dow Jones Industrial Average (DJINDICES: ^DJI) might be the best-known of the major stock market indexes, but experienced investors know that the S&P 500 (SNPINDEX: ^GSPC) is the index that best reflects the overall market. As the name implies, the index holds 500 of the top U.S. large-cap stocks. In order to join it, a company must be based in the U.S., be profitable on a generally accepted accounting principles (GAAP) basis over its last four quarters, and have a "large-cap" market cap, generally meaning above $10 billion.

Motley Fool 12 hours ago

APP

TTD

^GSPC
Is Merck the Next Big Weight-Loss Stock?

Merck (NYSE: MRK) is hungrily looking to take a bite out of the weight-loss drugs market. Merck on Dec. 16 said it had just inked a license agreement with a Chinese biopharma company called Hansoh Pharma that could presage its merits as a weight-loss stock in the coming years. Per the terms of that deal, Merck will get the exclusive worldwide rights to develop and then sell HS-10535, a preclinical-stage candidate that could potentially be useful for treating a few high-profile cardiometabolic disorders, including obesity and perhaps type 2 diabetes.

Motley Fool 13 hours ago

NVO
3 Stocks That Could Join the Trillion-Dollar Market Cap Club Next Year

Berkshire Hathaway was briefly a member of the group, but its market cap has dipped slightly below the threshold this month. Thanks to the artificial intelligence (AI) boom, a resilient U.S. economy, and falling interest rates, membership in the club isn't quite as exclusive as it once was. Assuming this bull market continues in 2025, there are a few more companies that could reach a $1 trillion market cap -- including these three.

Motley Fool 14 hours ago

WMT

JPM

LLY
Better Semiconductor Stock: Wolfspeed vs. Nvidia

Sales in the semiconductor industry are surging thanks to the secular trends of artificial intelligence (AI) and electric vehicles (EVs). The semiconductor market is forecast to reach more than $600 billion in 2024, and rise to $1 trillion by 2030, making investments in chip companies a good way to capitalize on this growth. Two semiconductor industry leaders to consider are Wolfspeed (NYSE: WOLF) and Nvidia (NASDAQ: NVDA).

Motley Fool yesterday

NVDA

WOLF
AppLovin (APP) Gets Buy Rating from Jefferies with $400 Target, Highlighting AI-Driven Growth

We recently published a list of 10 Buzzing AI Stocks on Latest News and Ratings. In this article, we are going to take a look at where AppLovin Corporation (NASDAQ:APP) stands against other buzzing AI stocks on latest news and ratings. Predictions of artificial intelligence reaching human-level intelligence have been made for over 50 years. […]

Insider Monkey yesterday

APP
AppLovin Stock (APP) May Struggle for More Momentum after 687% Rally

I invested in AppLovin (APP) when the company was worth less than $15 billion. Today, that figure stands at over $113 billion after a 687% rally over 12 months. However, I’m a little concerned that the momentum might be running low simply because the company’s valuation may prove unsustainable unless it can present further catalysts. For now, I’m neutral on this stock, given the evolving interest rate environment, the potential for more risk-off sentiment, and the stock’s valuation. What’s Drive

TipRanks yesterday

APP
Walmart, GM, Nvidia, Robinhood: All had an award-winning 2024

Yahoo Finance shook things up this year, not just naming a Company of the Year but also Surprise of the Year, Product of the Year, and Comeback of the Year. Walmart (WMT) was named Yahoo Finance's 2024 Comeback of the Year on the strength of its stock and earnings performance. Yahoo Finance Executive Editor Brian Sozzi spoke with CEO Doug McMillon about how the retailer's big investments have been paying off, while CFO John David Rainey explained that the company's recent success didn't happen by accident. Yahoo Finance's Surprise of the Year was General Motors (GM). CEO Mary Barra credits the automaker's diverse portfolio for its big success. Bank of America auto analyst John Murphy also weighed in to give his take on what could be next for the stock. Nvidia's (NVDA) AI-focused Blackwell platform was named Product of the Year. Comeback of the Year went to Robinhood (HOOD). Its stock has surged and it made big headway in diversifying its product offerings. CEO Vlad Tenev discusses what's next for the company while Mizuho senior analyst Dan Dolev argues Robinhood is a stock to own under the incoming Trump administration. Watch more Yahoo Finance Awards coverage here: Why Walmart is clobbering its rivals Walmart rolled back DEI efforts & others may too. Here's why. The 'exciting' part of Robinhood's growth is still ahead: Analyst

Yahoo Finance Video yesterday

WMT

NVDA

HOOD
Doc visits for weight loss drugs, Walmart body cams, and 2025 predictions: Business news roundup

Popular weight-loss drugs like Wegovy and Zepbound are boosting the use of healthcare in the U.S., leading to an uptick in patients getting diagnosed and starting prescriptions for other conditions, according to a new analysis by health data firm Truveta.

Quartz yesterday

WMT
If You Bought 1 Share of Walmart at Its IPO, Here's How Many Shares You Would Own Now

It's hard to fathom a world without Walmart (NYSE: WMT). If you were lucky and astute enough to buy just one share during its early days as a public company, you'd have many more due to subsequent stock splits. Exactly how many shares would you own?

Motley Fool yesterday

WMT
Tilray's CEO Makes a Bold Prediction: Is the Stock a Buy?

It's not a secret: The cannabis industry has been a major disappointment since Canada legalized recreational use in 2018. Tilray's CEO, Irwin Simon, recently made a bold prediction along those lines. Is legalization on the way in the U.S.?

Motley Fool yesterday

TLRY
Novo obesity data positive for Eli Lilly and Amgen, says UBS

UBS analyst Trung Huynh says Novo Nordisk’s (NVO) CagriSema Phase 3 topline obesity data “underwhelmed,” a positive read-through to Eli Lilly (LLY) and Amgen (AMGN). CagriSema achieved an average weight loss of 20.4%, below Novo’s prior guidance of 25% and inferior to Lilly’s tirzepatide at a similar timepoint, the analyst tells investors in a research note. UBS views the CagriSema’s obesity readout a positive read-through to Lilly, “validating again tirzepatide’s best-in-class profile.” It also

TipRanks yesterday

NONOF

NVO

AMGN
Jefferies sees Novo dropping ‘at least’ 10%-15% on obesity data

Jefferies analyst Peter Welford says the first headline from Novo Nordisk’s (NVO) Phase III CagriSema obesity data “disappoint” with 20.4% absolute weight loss and patient adherence likely suggesting tolerability concerns. The firm’s buy-side survey suggested most anticipated 25%-27% absolute weight loss with fastrointestinal tolerability to be broadly similar to Wegovy. Jefferies notes its $7.75B peak CagriSema sales are well below the $20B-plus consensus. It expects the Novo shares to be down

TipRanks yesterday

NONOF

NVO
Weight loss seen with Novo’s CagriSema weaker than expected, says BofA

BofA analyst Sachin Jain notes that Novo Nordisk (NVO) shares are down about 25%, which is “what we expected in this data scenario,” as CagriSema weight loss data is not as differentiated compared to Eli Lilly’s (LLY) Zepbound as was expected. Weight loss in the REDEFINE 1 trial at about 20.4% is “essentially in line” with Zepbound at 21%, and not high enough to create a barrier relative to future competition, says the analyst. With that said, the data is still superior to Wegovy and sufficient

TipRanks yesterday

LLY

NONOF

NVO
3 Fantastic Stocks That Could Enjoy a Santa Claus Rally

Santa Claus will soon be on his way delivering presents to kids around the world. Three Motley Fool contributors think they've identified fantastic stocks that could be in a good position to benefit from a Santa Claus rally. Here's why they chose AbbVie (NYSE: ABBV), Novo Nordisk (NYSE: NVO), and Vertex Pharmaceuticals (NASDAQ: VRTX).

Motley Fool yesterday

VRTX

NVO

ABBV
Why The 33% Return On Capital At AppLovin (NASDAQ:APP) Should Have Your Attention

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Amongst other things...

Simply Wall St. yesterday

APP
How to Build a High-Quality Passive Income-Producing Real Estate Portfolio for Less Than $250 at a Time

Investing in real estate can be a fantastic way to generate passive income. Rental properties typically throw off more cash than their monthly expenses, enabling investors to pocket the difference as passive income. There are lots of ways to invest in rental properties.

Motley Fool yesterday

O

EXR

INVH
Is Now a Good Time to Buy the Dip in Eli Lilly Stock?

Since Eli Lilly reported third-quarter earnings on Oct. 30, its shares have had a prolonged sell-off.

Motley Fool yesterday

LLY

NVO

Performance Overview

Return	DCLT	S&P 500
YTD	+4.76%	+24.34%
1-Year	-29.03%	+24.38%
3-Year	-68.12%	+28.36%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Data Call Technologies, Inc. (DCLT)

Related News

The comeback of REITs: Top ways to play commercial real estate

Donald Trump’s Agenda Has New Enforcers: Charlie Kirk and a Legion of Influencers

Is Occidental Petroleum (OXY) the Top Oil and Gas Stock To Invest In According to Hedge Funds?

Prediction: These 2 Stocks Will Join the S&P 500 in 2025

Is Merck the Next Big Weight-Loss Stock?

3 Stocks That Could Join the Trillion-Dollar Market Cap Club Next Year

Better Semiconductor Stock: Wolfspeed vs. Nvidia

AppLovin (APP) Gets Buy Rating from Jefferies with $400 Target, Highlighting AI-Driven Growth

AppLovin Stock (APP) May Struggle for More Momentum after 687% Rally

Walmart, GM, Nvidia, Robinhood: All had an award-winning 2024

Doc visits for weight loss drugs, Walmart body cams, and 2025 predictions: Business news roundup

If You Bought 1 Share of Walmart at Its IPO, Here's How Many Shares You Would Own Now

Tilray's CEO Makes a Bold Prediction: Is the Stock a Buy?

Novo obesity data positive for Eli Lilly and Amgen, says UBS

Jefferies sees Novo dropping ‘at least’ 10%-15% on obesity data

Weight loss seen with Novo’s CagriSema weaker than expected, says BofA

3 Fantastic Stocks That Could Enjoy a Santa Claus Rally

Why The 33% Return On Capital At AppLovin (NASDAQ:APP) Should Have Your Attention

How to Build a High-Quality Passive Income-Producing Real Estate Portfolio for Less Than $250 at a Time

Is Now a Good Time to Buy the Dip in Eli Lilly Stock?

Performance Overview